Winst gevend schreef op 8 mei 2024 21:13:
Stephen Toor May 8, 2024
Chief Commercial Officer
Commercial update:"83 patients on paid therapy at end 1Q 2024, with 5 additional enrollments pending authorization
Over 50 diagnosed patients (12+) not yet enrolled and over 50 pediatric patients
1Q 2024 revenue US $9.6M (+21% vs. 4Q 2023)
Includes US $1.1M Europe and RoW revenue
Over 500 APDS patients in the U.S. with over 220 diagnosed at end 1Q 2024
Over 15 diagnosed patients in 1Q 2024, including patients diagnosed via VUS resolution."
Situatie van eind maart 2024.